Single Peptides · Exact presentation
HGH 191AA · 10IU Vial
HGH 191AA · 10IU Vial is an exact single peptide or compound entry. This strength is kept separate because concentration and calculations depend on vial amount.
Educational research information for this exact variation. It is not medical advice, a prescription, or proof of regulatory approval.
Separate commercial record
Availability in the Dominican Republic
This educational entry is separate from the live catalog. Check the exact commercial record for current availability, price, and lot documentation. View exact commercial record.
HGH 191AA (3.33 mg Vial) Dosage Protocol
The source chart summarizes “200 mcg–900 mcg” at “Daily” frequency as educational information. PeptidosRD does not convert it into a clinical recommendation; any protocol must be checked against primary studies, applicable labeling, and qualified oversight.
Dosing & Reconstitution Guide
No reconstitution extrapolation is published because the unit, formulation, or composition does not support one reliable calculation from the source inventory. Reference concentration stated by the source: 1.11 mg/mL. It must be checked against the actual formulation and documentation.
Standard / Gradual Titration (3 mL = ~1.11 mg/mL)
The source chart summarizes “200 mcg–900 mcg” at “Daily” frequency as educational information. PeptidosRD does not convert it into a clinical recommendation; any protocol must be checked against primary studies, applicable labeling, and qualified oversight.
Standard / Gradual Titration (3 mL = ~1.11 mg/mL)
| Week | Daily Dose (mcg) | Units (per injection) (mL) |
|---|---|---|
| Week 1 | 200 mcg | 18 units (0.18 mL) |
| Week 2 | 300 mcg | 27 units (0.27 mL) |
| Week 3 | 400 mcg | 36 units (0.36 mL) |
| Week 4 | 500 mcg | 45 units (0.45 mL) |
| Week 5 | 600 mcg | 54 units (0.54 mL) |
| Week 6 | 700 mcg | 63 units (0.63 mL) |
| Week 7 | 800 mcg | 72 units (0.72 mL) |
| Week 8 | 900 mcg | 81 units (0.81 mL) |
Extended 12-Week Protocol (Optional)
The source chart summarizes “200 mcg–900 mcg” at “Daily” frequency as educational information. PeptidosRD does not convert it into a clinical recommendation; any protocol must be checked against primary studies, applicable labeling, and qualified oversight.
Extended 12-Week Protocol (Optional)
| Week | Daily Dose (mcg) | Units (per injection) (mL) |
|---|---|---|
| Week 9 | 1000 mcg | 90 units (0.90 mL) |
| Week 10 | 1100 mcg | 99 units (0.99 mL) |
| Week 11 | 1200 mcg | 108 units (1.08 mL) |
| Week 12 | 1300 mcg | 117 units (1.17 mL) |
Reconstitution Steps
No reconstitution extrapolation is published because the unit, formulation, or composition does not support one reliable calculation from the source inventory. Reference concentration stated by the source: 1.11 mg/mL. It must be checked against the actual formulation and documentation.
Storage Instructions
Proper storage preserves peptide quality.
Lyophilized: Store at −20 °C (−4 °F) in dry, dark conditions; stable for 1+ year.[5]
Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); use within 3–4 weeks and avoid freeze–thaw.[6]
Allow vials to reach room temperature before opening to reduce condensation uptake.
How This Works
It relates to the growth-hormone-releasing hormone, secretagogue receptor, and GH/IGF-1 axis. Each molecule acts at a different point and should not be treated as interchangeable.
Potential Benefits & Side Effects
GH/IGF-1 signaling is systemic and may carry metabolic, endocrine, and proliferative risks. No clinical regimen is provided here.
Potential Benefits
Evidence ranges from medicines authorized for limited indications to experimental secretagogues with sparse human data. Evidence for the ingredient, formulation, and use must be separated.
Source trail
Scientific references and source discovery
- PeptideDosages — exact HGH 191AA · 10IU Vial entrysecondary-structure
- PubMed — literature search for HGH 191AAprimary-discovery
- ClinicalTrials.gov — study search for HGH 191AAtrial-registry
- View Sourcesource-reference
- View Sourcesource-reference